Want to see CH:DOCM full AI Analyst Report?
DOCM Stock Chart & Stats
CHF6.61
CHF0.36(1.86%)
At close: 4:00 PM EST
CHF6.61
CHF0.36(1.86%)
Day’s Range― - ―
52-Week RangeCHF3.92 - CHF9.40
Previous CloseN/A
Volume45.75K
Average Volume (3M)342.18K
Market Cap
CHF424.54M
Enterprise ValueCHF581.69M
Total Cash (Recent Filing)CHF149.92M
Total Debt (Recent Filing)CHF288.64M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding52,400,000
10 Day Avg. Volume377,518
30 Day Avg. Volume342,178
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF6.50Price Target Upside-1.66% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-1.78
Revenue Forecast (FY)CHF1.22B
Bulls Say, Bears Say
Bulls Say
High‑margin Digital Services GrowthRapid 110% growth in Digital Services signals a durable shift toward higher‑margin revenue mix. As take‑rate and retail‑media scale, gross margin and CM3 contribution improve, supporting sustainable operating leverage and offsetting low‑margin Rx retail over the medium term.
TeleClinic Scale & Take‑rate RevenueTeleClinic's scale (≈2m treatments) establishes a differentiated digital care platform and recurring take‑rate revenue. This lowers incremental cost of service, strengthens customer engagement and cross‑sell potential, and creates a defensible, high‑margin growth engine over the coming years.
Improving Leverage And Liquidity BufferA stronger balance sheet and CHF 160m liquidity provide runway to execute the profitability roadmap. Lower net debt and a ~50% equity ratio reduce near‑term refinancing pressure, enabling investments in digital scale and margin programs while management works toward breakeven.
Bears Say
Persistent Negative Cash FlowConsistent and worsening cash burn undermines financial flexibility: negative OCF and FCF imply the company will need external funding unless execution quickly reduces cash outflows. This constrains strategic optionality and raises refinancing risks until FCF turns positive (management target 2027).
Ongoing Operating LossesSustained negative margins and sizable adjusted EBITDA losses mean returns on equity are negative and capital is consumed rather than generated. Even with revenue growth, profitability recovery is required to justify ongoing investment and to sustain credit metrics beyond the current liquidity runway.
Logistics, Marketing & Working‑capital HeadwindsRising logistics and marketing costs plus working‑capital inefficiencies materially pressure margins and cash flow. These operational frictions are structural unless solved (network/fulfilment changes, customer pricing, receivables discipline), and could blunt margin recovery even as digital revenues scale.
DOCM FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was CHF3.92 and its highest was CHF9.39 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF424.54M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Aug 19, 2026 which is in 39 days.
How were DocMorris AG’s earnings last quarter?
Currently, no data Available
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Overvalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 52,400,000 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in CH:DOCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
DOCM Stock 12 Month Forecast
Average Price Target
CHF6.50
▼(-1.66% Downside)
Technical Analysis
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
Galenica AG
―
Galderma Group AG
―
medmix AG
―
Options Prices
Currently, No data available
---